Brief: NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients With Bipolar Depression Acute Suicidality
03/01/2023 11:48
Jan 3 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS INITIATES PHASE 3 TRIAL TREATING
PATIENTS
WITH BIPOLAR DEPRESSION WITH ACUTE SUICIDALITY - FIRST CLINICAL
SITE CONTRACTED
* NRX PHARMACEUTICALS INC - FIRST TRIAL SITE HAS BEEN
CONTRACTED
WITH OTHERS EXPECTED IN NEAR FUTURE, FIRST DOSING OF PATIENTS IS
EXPECTED IN EARLY 2023
* NRX PHARMACEUTICALS INC - A TYPE B MEETING WITH FDA'S
PSYCHIATRY
DIVISION IS SCHEDULED IN MID-JANUARY 2023
Source text for Eikon: ID:nPn1F7L0la
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview